New RarePlex® Developer Kits for CTC characterization provide researchers flexibility in independent CTC assay developmentSEATTLE, Oct. 29, 2019 - RareCyte® announces the launch of the of RarePlex® Developer Kits that uniquely enable customers to add their own biomarkers to RareCyte circulating tumor cell (CTC) assays in their own lab. Kyla Teplitz, Sr. Product Manager said, "The understanding of cancer heterogeneity and evolution is a rapidly evolving field, and it is important that our customers have the tools that allow them to keep pace. We are excited to launch our Developer platform to enable our customers to create their own CTC assays while leveraging RareCyte's robust liquid biopsy platform."
RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting in AtlantaSeattle, WA, March 28, 2019 – RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting in Atlanta, March 29 through April 3. These next generation CyteFinder Instruments expand on RareCyte’s world class liquid biopsy platform to support tissue workflows. Both instruments perform rapid, whole slide imaging in seven fluorescence channels as well as brightfield for IF, IHC, and H&E samples and are designed for placement in clinical laboratories. Together, the CyteFinder II systems provide one platform for fast, multiplexed imaging with multi-omic results.
RareCyte expands liquid biopsy offerings with the RarePlex™ CTC Developer Kit for custom biomarkers, and introduces the next generation CytePicker® Cell Retrieval Module for single cell and tissue micro-region retrieval
Seattle, WA, March 11, 2019 – RareCyte, Inc., a global rare cell detection and liquid biopsy company, announces its newest products, the RarePlex™ CTC Developer Kit, and the next generation CytePicker® Cell Retrieval Module in conjunction with the Molecular Med Tricon Meeting in San Francisco March 10 through 15. The RarePlex CTC Developer Kit leverages the robust detection and enumeration of circulating tumor cells (CTCs) of the RareCyte base CTC detection assay and enables characterization of those CTCs with up to two custom biomarkers. This capability enables customers to independently innovate and create a wide range of CTC detection assays utilizing biomarkers of interest and expand on the RareCyte liquid biopsy platform.
Molecular Med Tri-Con 2020
1-4 March 2020
Moscone South Convention Center
San Francisco, CA